Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
Sibylle Jablonka, Luisa Hennlein, Michael Sendtner
Neurological Research and Practice (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Sex and Gender Differences in Neurodegenerative Diseases: Challenges for Therapeutic Opportunities
Annalisa Bianco, Ylenia Antonacci, Maria Liguori
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6354-6354
Open Access | Times Cited: 39
Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor
Qing Xie, Xiupeng Chen, Hong Ma, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 4, pp. 945-965
Open Access | Times Cited: 10
From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders
Elisa Duranti, Chiara Villa
Biology (2024) Vol. 13, Iss. 9, pp. 719-719
Open Access | Times Cited: 9
Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression
Hildegund C.J. Ertl
Drugs (2023) Vol. 83, Iss. 4, pp. 287-298
Closed Access | Times Cited: 19
Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints
Mary M. Reilly, David N. Herrmann, Davide Pareyson, et al.
Annals of Neurology (2023) Vol. 93, Iss. 5, pp. 906-910
Open Access | Times Cited: 17
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
D. L. Price, Asma Khan, Rachel Angers, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 17
Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy
P. S. Bagga, Sudhakar Singh, Gobind Ram, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 7
A knock down strategy for rapid, generic, and versatile modelling of muscular dystrophies in 3D-tissue-engineered-skeletal muscle
Stijn L.M. in ‘t Groen, Marnix Franken, Theresa Bock, et al.
Skeletal Muscle (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Molecular Insights into IQSEC2 Disease
Nina S. Levy, Veronika Borisov, Orit Lache, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4984-4984
Open Access | Times Cited: 12
Gene therapy in pediatrics – Clinical studies and approved drugs (as of 2023)
Tahereh Mohammadian, Fatemeh Zahedipour, Paul Trosien, et al.
Life Sciences (2024) Vol. 348, pp. 122685-122685
Open Access | Times Cited: 4
Prospects for gene replacement therapies in amyotrophic lateral sclerosis
Ilaria Giovannelli, Adrian Higginbottom, Janine Kirby, et al.
Nature Reviews Neurology (2022) Vol. 19, Iss. 1, pp. 39-52
Closed Access | Times Cited: 17
Spinal Muscular Atrophy (SMA): Treatment strategies, challenges and future prospects
Nikunja Kishor Mishra, Amiyakanta Mishra
Deleted Journal (2025), pp. 100031-100031
Closed Access
Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology
Rupal Dhariwal, Mukul Jain, Y. Mir, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Orthopedic Manifestations of Spinal Muscular Atrophy: Clarified and Unresolved Theoretical and Practical Issues
A.М. Zyma, Yu.M. Huk, A.V. Smaha, et al.
TERRA ORTHOPAEDICA (2025), Iss. 4(123), pp. 32-38
Closed Access
Current amyloid inhibitors: therapeutic applications and nanomaterial-based innovations
Paula López-García, María M. Tejero-Ojeda, Marisela Morales, et al.
Progress in Neurobiology (2025), pp. 102734-102734
Closed Access
Advanced strategies for screening and identifying RNA-targeted small molecules: Bridging therapeutic potential and innovation
Zukela Ruzi, Daxiong Han, Kailibinuer Aierken
Results in Chemistry (2025), pp. 102305-102305
Open Access
Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases
Maximilian Vidovic, Mario Menschikowski, Maren Freigang, et al.
Neurological Research and Practice (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice
Marina Boido, Iacopo Gesmundo, Anna Caretto, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 2
Open Access | Times Cited: 8
Western Australian women's expectations for expanded NIPT—An online survey regarding NIPT for single gene, recessive and chromosomal conditions
Sarah S. Long, Peter O’Leary, Jan E. Dickinson
Journal of Genetic Counseling (2023) Vol. 32, Iss. 5, pp. 1047-1056
Open Access | Times Cited: 8
Gene therapy in polycystic kidney disease: A promising future
Cheng Xue, Jiayi Lv, Bo Yang, et al.
Journal of Translational Internal Medicine (2024) Vol. 12, Iss. 6, pp. 543-552
Closed Access | Times Cited: 2
Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME): three new cases and review of the mutational spectrum
Ali Najafi, Behnoosh Tasharrofi, Farshid Zandsalimi, et al.
˜The œItalian Journal of Pediatrics/Italian journal of pediatrics (2023) Vol. 49, Iss. 1
Open Access | Times Cited: 6
OPTN gene therapy increases autophagy and protects mitochondria in SOD1‐G93A‐expressing transgenic mice and cells
Di Wen, Yingxiao Ji, Yuanyuan Li, et al.
FEBS Journal (2023) Vol. 291, Iss. 4, pp. 795-813
Closed Access | Times Cited: 6
Disease Mechanisms and Therapeutic Approaches in SMARD1—Insights from Animal Models and Cell Models
Sibylle Jablonka, Ezgi Yildirim
Biomedicines (2024) Vol. 12, Iss. 4, pp. 845-845
Open Access | Times Cited: 2
Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy
John Day, Jerry R. Mendell, Arthur H.M. Burghes, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 31, pp. 101117-101117
Open Access | Times Cited: 5
Artificial Intelligence in The Management of Neurodegenerative Disorders
Sanchit Dhankhar, Somdutt Mujwar, Nitika Garg, et al.
CNS & Neurological Disorders - Drug Targets (2023) Vol. 23, Iss. 8, pp. 931-940
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top